Century Therapeutics, Inc. (IPSC)
NASDAQ: IPSC · Real-Time Price · USD
2.560
0.00 (0.00%)
At close: Mar 6, 2026, 4:00 PM EST
2.560
0.00 (0.00%)
After-hours: Mar 6, 2026, 5:24 PM EST
Century Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 113.34 | 6.59 | 2.24 | 5.2 | - | - | |
| Revenue Growth (YoY) | 4122.69% | 194.81% | -57.01% | - | - | - | |
| Cost of Revenue | 105.35 | 107.24 | 92.71 | 97.17 | 75.65 | - | |
| Gross Profit | 7.99 | -100.66 | -90.48 | -91.97 | -75.65 | - | |
| Selling, General & Admin | 30.66 | 34.51 | 34.71 | 31.86 | 19.24 | 9.5 | |
| Research & Development | - | - | - | - | - | 39.68 | |
| Operating Expenses | 30.66 | 34.51 | 34.71 | 31.86 | 19.24 | 49.18 | |
| Operating Income | -22.67 | -135.17 | -125.18 | -123.83 | -94.88 | -49.18 | |
| Interest Expense | - | - | -0.54 | -1.43 | -1.28 | -0.38 | |
| Interest & Investment Income | 8.92 | 13.01 | 12.68 | 4.42 | 0.38 | 0.7 | |
| Other Non Operating Income (Expenses) | 0.28 | 0.35 | -0.38 | - | - | - | |
| EBT Excluding Unusual Items | -13.48 | -121.81 | -113.43 | -120.84 | -95.78 | -48.85 | |
| Impairment of Goodwill | -4.33 | -4.33 | - | - | - | - | |
| Asset Writedown | -6.76 | - | -16.37 | - | - | - | |
| Other Unusual Items | -0.14 | 1.36 | - | - | - | - | |
| Pretax Income | -24.71 | -124.78 | -134.79 | -130.84 | -95.78 | -53.58 | |
| Income Tax Expense | 1.78 | 1.79 | 1.88 | 0.09 | 0.04 | - | |
| Net Income | -26.48 | -126.57 | -136.67 | -130.93 | -95.82 | -53.58 | |
| Net Income to Common | -26.48 | -126.57 | -136.67 | -130.93 | -95.82 | -53.58 | |
| Shares Outstanding (Basic) | 86 | 79 | 59 | 58 | 32 | 7 | |
| Shares Outstanding (Diluted) | 86 | 79 | 59 | 58 | 32 | 7 | |
| Shares Change (YoY) | 19.08% | 32.60% | 2.70% | 78.30% | 332.95% | 10.43% | |
| EPS (Basic) | -0.31 | -1.61 | -2.30 | -2.27 | -2.96 | -7.16 | |
| EPS (Diluted) | -0.31 | -1.61 | -2.30 | -2.27 | -2.96 | -7.16 | |
| Free Cash Flow | -113.16 | -110.29 | -102.08 | -16.55 | -133.97 | -51.09 | |
| Free Cash Flow Per Share | -1.31 | -1.40 | -1.72 | -0.29 | -4.14 | -6.83 | |
| Operating Margin | -20.00% | -2051.39% | -5600.94% | -2381.82% | - | - | |
| Profit Margin | -23.37% | -1920.87% | -6115.12% | -2518.41% | - | - | |
| Free Cash Flow Margin | -99.85% | -1673.84% | -4567.52% | -318.37% | - | - | |
| EBITDA | -9.8 | -121.86 | -112.14 | -115.39 | -91.14 | -47.77 | |
| D&A For EBITDA | 12.87 | 13.3 | 13.04 | 8.44 | 3.75 | 1.4 | |
| EBIT | -22.67 | -135.17 | -125.18 | -123.83 | -94.88 | -49.18 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.